New vaccine combo aims to supercharge immune attack on prostate cancer
NCT ID NCT04989946
First seen Jun 25, 2026 · Last updated Jul 02, 2026 · Updated 2 times
Summary
This study is testing whether adding a DNA vaccine (pTVG-AR) and immune checkpoint blockers (nivolumab or cemiplimab) to standard hormone therapy can improve outcomes for men with newly diagnosed, high-risk prostate cancer. About 60 participants will receive different combinations before having their prostate removed. The main goals are to see if the cancer completely disappears in the removed tissue and to check for side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- pTVG-AR (DNA vaccine), nivolumab, cemiplimab, degarelix
- What this could lead to
- If successful, this could lead to a new combination therapy that helps the immune system better attack prostate cancer cells, potentially reducing the risk of cancer returning after surgery.
- What could go wrong
- This is an early-phase trial with only 60 participants, so results may not apply to all patients. The vaccine and immune drugs can cause side effects like fatigue, infusion reactions, or immune-related inflammation.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin, 53792, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new tracer light up hidden prostate cancer?
- Could deep breaths before surgery ward off Post-Op confusion?
- A second look: MRI screening may spot hidden prostate cancers
- Can precision protons spare the bowel in prostate cancer?
- AI coaches doctors on cancer risk talks
- Can an immune booster make hormone therapy work better against prostate cancer?